Charles River Laboratories (CRL) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Total Assets Chart for Charles River Laboratories
Charles River Laboratories (CRL) total assets for FY2025 were USD 7.1B, a -5.2% change from FY2024. Charles River Laboratories's total assets grew from USD 234.3M in 1998 to USD 7.1B in 2025 (2946.0% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 5.4%, 10-year CAGR of 13.2%, 20-year CAGR of 5.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $12.68B
- Implied Share Price
- $265.51
- Enterprise Value
- $14.14B
- Revenue (TTM)
- $4.00B
- EBITDA
- $836.13M
- Profit Margin
- -5.96%
- Trailing P/E
- —
- Forward P/E
- 21.05
- Price/Book (MRQ)
- 3.83
- Price/Sales (TTM)
- 3.20
- EV/EBITDA
- 48.67
- EV/Revenue
- 3.51
- Dividend Yield
- —
- Book Value
- $64.30
- Free Cash Flow (FY2025)
- $518.49M
- Free Cash Flow Yield
- 4.09%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.